Company: EDSA
Filing Date: 2025-12-12
Form Type: 10-K
Source: 0001171843-25-007914
Chunk: 306

Company: Edesa Biotech, Inc.
Filing Date: 2025-12-12
Form: 10-K
Item: Item 1A
Chunk 306
---
 September 30, 2025 compared to $7.0 million for the prior year.

			●

			The following table summarizes our R&D expenses incurred for the years ended September 30, 2025 and 2024, together with the dollar increase or decrease in those items:

			Fiscal Year End

			Change

			September 30, 2025

			September 30, 2024

			Program-specific external costs:

			EB06

			$
			339,816

			$
			-

			$
			339,816

			EB05

			1,929,023

			1,444,949

			484,074

			Other development and discovery programs

			133,347

			218,391

			(85,044
			)

			Total program-specific costs

			2,402,186

			1,663,340

			738,846

			Unallocated internal costs

			Non-program specific external costs

			1,206

			9,652

			(8,446
			)

			Unallocated internal costs

			1,265,346

			1,208,975

			56,371

			Total unallocated internal costs

			1,266,552

			1,218,627

			47,925

			Total research and development costs

			3,668,738

			2,881,967

			786,771

			●

			Research and development (“R&D”) expenses increased by $0.8 million to $3.7 million for the year ended September 30, 2025 compared to $2.9 million for the prior year primarily due to increased expenses for manufacturing-related activities and other preparations for the planned Phase 2 clinical study of EB06 in vitiligo patients, as well as increased research expenses related to the completion of the Phase 3 study of paridiprubart (EB05) and supply costs for the ongoing United States government-funded study of paridiprubart, partially offset by lower spend on other development programs. Our R&D expenses consist primarily of employee-related expenses, including salaries, benefits, taxes, travel, and share-based compensation expense for personnel in R&D functions; expenses related to process development and production of product candidates